Current and Emerging Targets in Immunotherapy for Osteosarcoma

被引:84
|
作者
Miwa, Shinji [1 ]
Shirai, Toshiharu [1 ,2 ]
Yamamoto, Norio [1 ]
Hayashi, Katsuhiro [1 ]
Takeuchi, Akihiko [1 ]
Igarashi, Kentaro [1 ]
Tsuchiya, Hiroyuki [1 ]
机构
[1] Kanazawa Univ, Sch Med, Dept Orthopaed Surg, Kanazawa, Ishikawa 9208640, Japan
[2] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Orthopaed, Kyoto 6028566, Japan
关键词
SOFT-TISSUE SARCOMA; LIPOSOMAL MURAMYL TRIPEPTIDE; AUTOLOGOUS TUMOR LYSATE; HIGH-GRADE OSTEOSARCOMA; PULSED DENDRITIC CELLS; DEATH LIGAND 1; T-CELLS; INTRAVENOUS-INJECTION; MONOCYTE ACTIVATION; REFRACTORY BONE;
D O I
10.1155/2019/7035045
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Osteosarcoma is the most common primary malignancy of bone. Although outcomes of patients with osteosarcoma have improved since the introduction of chemotherapy, outcomes of metastatic or unresectable osteosarcomas are still unsatisfactory. To improve osteosarcoma outcomes, the development of novel systemic therapies for osteosarcoma is needed. Since the 1880s, various immunotherapies have been utilized in patients with osteosarcoma and some patients have shown response to the treatment. Based on recent studies about the role of the immune system in malignancies, immunotherapies including immune modulators such as interleukin-2 and muramyl tripeptide, dendritic cells, immune checkpoint inhibitors, and engineered T cells have been utilized in patients with malignancies. Although there are limited reports of immunotherapies for osteosarcoma, immunotherapy is thought to be a promising treatment option for treating osteosarcomas. In this review, an overview of various immunotherapies for osteosarcoma is provided and their potential as adjuvant therapies is discussed.
引用
收藏
页数:8
相关论文
共 50 条
  • [31] Current State of Immunotherapy and Mechanisms of Immune Evasion in Ewing Sarcoma and Osteosarcoma
    Evdokimova, Valentina
    Gassmann, Hendrik
    Radvanyi, Laszlo
    Burdach, Stefan E. G.
    CANCERS, 2023, 15 (01)
  • [32] New emerging targets in cancer immunotherapy: the role of TIM3
    Friedlaender, Alex
    Addeo, Alfredo
    Banna, Giuseppe
    ESMO OPEN, 2019, 4
  • [33] Emerging Therapeutic Targets and Drug Resistance Mechanisms in Immunotherapy of Hematological Malignancies
    Olejarz, Wioletta
    Basak, Grzegorz
    CANCERS, 2023, 15 (24)
  • [34] New emerging targets in cancer immunotherapy: the role of LAG3
    Puhr, Hannah Christina
    Ilhan-Mutlu, Aysegul
    ESMO OPEN, 2019, 4 (02)
  • [35] Glycan Structures in Osteosarcoma as Targets for Lectin-Based Chimeric Antigen Receptor Immunotherapy
    Prasse, Nele
    Wessolowski, Charlotte
    Mueller, Ingo
    Cornils, Kerstin
    Franke, Anna-Katharina
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (10)
  • [36] Current and emerging drug targets in heart failure treatment
    Ghionzoli, Nicolo
    Gentile, Francesco
    Del Franco, Anna Maria
    Castiglione, Vincenzo
    Aimo, Alberto
    Giannoni, Alberto
    Burchielli, Silvia
    Cameli, Matteo
    Emdin, Michele
    Vergaro, Giuseppe
    HEART FAILURE REVIEWS, 2022, 27 (04) : 1119 - 1136
  • [37] Glioblastoma: Current Status, Emerging Targets, and Recent Advances
    Thakur, Amandeep
    Faujdar, Chetna
    Sharma, Ram
    Sharma, Sachin
    Malik, Basant
    Nepali, Kunal
    Liou, Jing Ping
    JOURNAL OF MEDICINAL CHEMISTRY, 2022, 65 (13) : 8596 - 8685
  • [38] Current and emerging drug targets in heart failure treatment
    Nicolò Ghionzoli
    Francesco Gentile
    Anna Maria Del Franco
    Vincenzo Castiglione
    Alberto Aimo
    Alberto Giannoni
    Silvia Burchielli
    Matteo Cameli
    Michele Emdin
    Giuseppe Vergaro
    Heart Failure Reviews, 2022, 27 : 1119 - 1136
  • [39] Current and emerging therapeutic targets for Parkinson’s disease
    Tanvi Pingale
    Girdhari Lal Gupta
    Metabolic Brain Disease, 2021, 36 : 13 - 27
  • [40] Current and Emerging Drug Targets for Human Immunodeficiency Virus
    Waheed, Abdul A.
    Tachedjian, Gilda
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2016, 16 (10) : 1072 - 1073